<DOC>
	<DOCNO>NCT00333359</DOCNO>
	<brief_summary>The primary objective trial ass long-term safety efficacy XP13512 ( Gabapentin Enacarbil ) take daily treatment patient suffer Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>XP13512 ( Gabapentin Enacarbil ) Extension Study Patients With Restless Legs Syndrome .</brief_title>
	<detailed_description>Study XP055 multicenter , open-label , 52-week extension study XP13512 ( Gabapentin Enacarbil [ GEn ] ) give daily eligible subject Restless Legs Syndrome ( RLS ) previously complete 1 follow study meet eligibility criterion : XP052 ( 110963 [ NCT00298623 ] ) , XP053 ( 111460 [ NCT00365352 ] ) , XP081 ( 111462 [ NCT01332305 ] ) , XP083 ( 111463 [ NCT01332318 ] ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients successfully complete one follow study : XP052 ( 110963 [ NCT00298623 ] ) , XP053 ( 111460 [ NCT00365352 ] ) , XP081 ( 111462 [ NCT01332305 ] ) , XP083 ( 111463 [ NCT01332318 ] ) . Subjects , opinion Investigator , would noncompliant study visit schedule , procedure , medication administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>